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Abstract
Botanical seed oils reduce the generation of leukotrienes in patients with asthma.
Our objective was to determine the efficacy of a botanical seed oil combination against airflow obstruction in asthma,
and to determine the pharmacogenomic effect of the leukotriene C4 synthase (LTC4S) polymorphism A-444C.
We conducted a randomized, double-blind, placebo-controlled, cross-over clinical trial in mild to moderate asthmatics
to determine the change in FEV1 after 6 weeks of therapy with borage and echium seed oils versus corn oil placebo.
We also examined the effect of the variant LTC4S -444C allele on the change in lung function.
We did not identify a difference in FEV1 in the study cohort as a whole (n = 28), nor in the group of A homozygotes. In
the C allele carriers (n = 9), FEV1 improved by 3% after treatment with borage and echium seed oils and declined by
4% after placebo corn oil (p = 0.02). All 9 C allele carriers demonstrated an improvement in their FEV1 on active
treatment compared to placebo as compared to only 7 out of 19 A allele homozygotes (p = 0.007). We observed
transient differences in ex vivo leukotriene generation from circulating basophils and granulocytes. We did not observe
significant differences in urinary LTE4 levels.
We conclude that compared to corn oil, a combination of borage and echium seed oils improves airflow obstruction
in mild to moderate asthmatics who carry the variant allele in the LTC4S gene (A-444C). Botanical oil supplementation
may have therapeutic potential in asthma if used in a personalized manner.
Trial registration: This trial was registered at www.clinicaltrials.gov as NCT00806442.
Keywords: Asthma; Borage oil; Echium oil; Leukotrienes; LTC4 synthase
Background
5-lipoxygenase (5-LO)-dependent oxidative metabolism of
arachidonic acid (AA) leads to generation of leukotrienes
(LTs), which are associated with airway inflammation in
asthma (Peters-Golden and Henderson 2007). Studies have
demonstrated that dietary supplementation with marine or
botanical seed oils containing omega-3 and omega-6
polyunsaturated fatty acids (PUFAs) can decrease air-
way inflammation by reducing the generation of leukotrienes
and pro-inflammatory cytokines, and attenuating neutrophil
function (Barros et al. 2011; Chilton-Lopez et al. 1996; Lee
et al. 1985).
Seed oils from the Boraginaceae family of plants,
including borage oil (Borago officinalis) and echium oil
(Echium plantagineum) contain medium chain omega-6
and omega-3 PUFAs, including γ-linolenic acid (GLA;18:3,
n-6), ʱ-linolenic acid (ALA;18:3,n-3) and stearidonic acid
(SDA;18:4,n-3) (Figure 1). GLA is efficiently converted by
cells and tissues to dihomo γ-linolenic acid (DGLA) that
competes with AA for substrate utilization by 5-LO, thus
having anti-inflammatory potential in asthma. However, the
conversion of ALA to long-chain omega-3 PUFAs such as
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) (both known to reduce leukotrienes) is poor in
humans, which is believed to be a result of the inefficiency
of the initial rate-limiting step (ʔ-6 desaturase, FADS2 gene)
involved in long-chain PUFA biosynthesis. However SDA is
downstream of ʔ-6 desaturase and is up to five-fold more
efficiently converted to EPA than ALA (James et al. 2003).
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triene generation from leukocytes in vitro (Guichardant
et al. 1993). Further, our preliminary dose-titration study
has suggested that a combination of 1.7 g/day of GLA and
0.8 g/day of SDA obtained from a mixture of borage and
echium seed oils can significantly reduce the generation of
leukotrienes from AA without impacting circulating AA
levels (Arm et al. 2013). However, the physiologic effects
of botanical seed oils on improvement in airflow obstruc-
tion in asthma are not known. Hence, we conducted a
randomized, double-blind, placebo-controlled, cross-over
clinical trial in mild to moderate asthmatics comparing
the change in forced expiratory volume in one second
(FEV1) after 6 weeks of therapy with the botanical oil
combination.
The ability of inflammatory cells to generate leukotri-
enes is influenced by polymorphisms in genes involved in
leukotriene synthesis (Sampson et al. 2000). Of particular
interest is a common A to C single nucleotide polymorph-
ism located 444 base pairs upstream of the gene encoding
leukotriene C4 synthase (LTC4S A-444C, rs730012). The
dominant variant C allele of the gene for LTC4 synthase
has been associated with an increase in cysteinyl LT
production, reduced lung function and increased effective-
ness of LT receptor antagonists against bronchoconstric-
tion in asthma (Sampson et al. 2000; Silverman et al. 1998;
Tantisira and Drazen 2009). To our knowledge, no studies
have examined whether the LTC4S variant allele has an
impact on the efficacy of PUFA supplementation on
physiologic outcomes associated with asthma. Hence we
hypothesized that dietary supplementation with the botan-
ical seed oil combination would improve airflow obstruction
in asthmatics when compared to placebo, preferentially in
those who carried the variant C allele at the LTC4S A-444C
locus.
Results
We enrolled 43 participants with mild to moderate asthma
and randomized 39, of which 28 completed the study
(Figure 2). Nine participants were found to carry at least
one copy of the variant C allele in the LTC4S promoter.
There were no significant differences in baseline clinical
characteristics between the two genotype groups (Table 1).
There was no difference in the change in FEV1 between
the botanical oil and placebo arms after 6 weeks of treat-
ment in the study cohort as a whole, and in the group of
A homozygotes. In contrast, in C allele carriers (n = 9),
the FEV1 improved 3% after treatment with combination
botanical oils and declined 4% after placebo corn oil (differ-
ence of 7% between drug and placebo, p = 0.02, Figure 3).
More importantly, all 9 individuals with the C allele, but only
7 of 19 individuals homozygous for the A allele, showed an
improvement in their FEV1 when receiving the botanical oil
combination compared to placebo (p = 0.007 for the per-
centage of responders, Figure 4).
Figure 1 Pathways for metabolism of omega-6 (left) and omega-3 (right) fatty acids in humans. The synthesis of long chain PUFAs from the
essential dietary medium chain PUFAs, α-linolenic acid (ˉ-3) and linoleic acid (ˉ-6). The fatty acids derived from borage oil (linoleic and gamma-linoleic
acids, both ˉ-6) and echium (stearidonic, ˉ-3; linoleic and gamma-linoleic acids, both ˉ-6) would be expected to enter the pathways as indicated.
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Table 1 Participant’s characteristics and study results
Characteristics and results A homozygotes (AA) C allele carriers (AC/CC)
N 19 9 (8 AC, 1 CC)
Age (years)
a 37± 14 (20 – 60) 29± 8 (18 – 39)
Sex (female/male) 14/5 8/1
Race (Caucasian/other) 15/4 7/2
Hispanic (yes/no) 1/18 3/6
ICS dose (ʼg fluticasone)
a 117±250 (0 – 1000) 85± 128 (0 – 267)
Baseline rescue inhaler use (puffs/week)
a 5±6(0– 18) 7±7 (0 – 20)
Baseline FEV1 (L)
a 2.24±0.51 (1.35 – 3.01) 2.31± 0.47 (1.75 – 3.26)
Baseline FEV1 (%)
a 69± 12 (51 – 89) 69± 9 (55 – 84)
Change in FEV1 after placebo (%) 1±9 (-21 – 18) −4± 6 (-15 – 3)
Change in FEV1 after drug (%)
a 1±5 (-11 – 9) 3±5 (-3 – 12)
Change in FEV1 after drug compared to placebo (%)
a* −1± 9 (-13 – 24) 7±5 (1 – 17)
*p value for difference between group means =0.02.
aMean ± standard deviation (minimum – maximum).
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genotypes and showed no changes in either group on
either arm of the study (data not shown). The two geno-
type groups showed similar levels of LTs generated by
basophils (with FcʵRI cross-linkage) and granulocytes
(with ionophore stimulation) before randomization. How-
ever, generation of ionophore-induced 5-lipoxygenase path-
way products was markedly reduced during treatment with
the botanical oil combination in the C allele carriers, but
not in the A allele homozygotes. This difference was
Figure 3 Change in FEV1 % predicted in participants from both genotype groups after 6 weeks of therapy with drug and placebo.
Horizontal bars represent group means.
Figure 4 Effect of 6 weeks of dietary supplementation with borage and echium seed oils on FEV1 compared to corn oil placebo in 28
mild to moderate asthmatics. The letters on the X axis demonstrate their leukotriene C4 synthase promoter polymorphism status
(A-444C, rs730012).
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(Figure 5a), but lost significance after six weeks. The majority
of the products detected were LTB4 and proximal 5-LO
pathway products (5-HETE and all-trans LTB4 (Figure 5b).
CysLT production as a fraction of the total did not vary
by genotype, and trend of CysLT generation tended to
follow the overall trend for 5-LO production, but the
difference between the treatment arms in the C allele
carriers after 3 weeks of treatment did not reach statistical
significance (p = 0.06, Figure 5c).
Overall, the treatment was well tolerated. We did not
observe liver dysfunction or a significant drop in hemoglobin
concentrations, which have been reported with botanical seed
oil consumption.
Discussion
This study demonstrates that a combination of omega-3 and
omega-6 dietary medium chain PUFAs (containing SDA and
GLA, respectively), provided over six weeks in a fixed ratio
in the form of borage and echium seed oils, results in a sig-
nificant difference in FEV1 compared with corn oil placebo
in subjects bearing at least one copy of a polymorphic LTC4S
allele in a small proof-of-concept crossover study. This is the
first study to suggest that botanical oil supplementation can
modify lung function and thus have therapeutic potential in
asthma if used in a personalized manner.
Dietary supplementation with omega-3 PUFAs from fish
oil significantly reduces exercise-induced bronchoconstric-
tion as well as concentrations of CysLTs and prostaglandins
in induced sputum in elite athletes (Mickleborough et al.
2006; Tecklenburg-Lund et al. 2010). Omega-3 PUFAS were
equivalent to the effects of the CysLT1 receptor antagonist
montelukast on blocking bronchoconstriction caused by
eucapnic hyperpnea in the latter study (Tecklenburg-Lund
et al. 2010). Nagakura et al. (2000) found that dietary sup-
plementation with fish oil rich in omega-3 PUFAs EPA
and DHA improves symptoms and airway hyper-
responsiveness in children with asthma living in a health
care facility with strictly controlled environment in terms
of inhalant allergens and diet. In a random sample of
adults in The Netherlands studied between 1994 and
1997, McKeever et al. (2008) found that a high intake of
omega-3 fatty acids does not protect against asthma, but a
high intake of several omega-6 fatty acids is associated
with a significant reduction in FEV1. They proposed that
the high dietary intake of omega-6 fatty acids, rather than
reduced omega-3 intake, may have an adverse effect on
lung health. There is a possible detrimental effect of oil
and fat consumption in asthma. Wood et al. (2011) exam-
ined the effect of a single high-fat meal versus low-fat
meal on the bronchodilator response to albuterol in asth-
matics. The high fat meal contained 48 g (49% of total en-
ergy) total fat, including 20.5 g (21% of total energy)
saturated fat. In our study, we did not control the diets
our subjects consumed while in the study; hence it is likely
they were all are eating a typical modern Western diet
which contains about 125 g of fat/day. Our protocol pro-
vided 9 g of fat given throughout the day and only a small
proportion (~2.5 g) of that were the proposed bio-actives
(GLA and SDA). Consequently it is unlikely that providing
this small amount of fat on top of such a background diet
would have had any impact on the clinical and other
parameters examined, based on the mass of the fat alone.
5-lipoxygenase (5-LO)-dependent oxidative metabol-
ism of arachidonic acid (AA) leads to generation of
pro-inflammatory leukotrienes (LTs). However, dihomo-
gamma-linoleic acid (DGLA), a precursor of AA, sup-
presses LTgeneration by competing with AA for substrate
utilization by 5-LO. Borage (Borago officinalis)s e e do i li sa
rich source of gamma linolenic acid (GLA), which is the
precursor of DGLA (Figure 1). Dietary supplementation with
Borage seed oil provides effective inhibition of leukotriene
Figure 5 Effects of dietary supplementation with borage and echium seed oils on 5-LO pathway product formation by ionophore-stimulated
peripheral blood granulocyte fractions from stable asthmatic subjects with AA and AC/CC LTC4S genotypes. a. Sum of total 5-LO pathway
products (5-HETE, all-trans-LTB4,L T B 4, and cys-LTs) generated per 1 × 10
6 ionophore-stimulated granulocytes in each indicated genotype after 3 and 6
weeks of treatment on each arm. b. Non-cys LTs (5-HETE, all-trans-LTB4,L T B 4) c. cys-LTs (LTC4,L T D 4, and LTE4) were measured for the same samples.
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biosynthesis from circulating granulocytes in vitro in cell
culture and ex vivo (Henz et al. 1999; Johnson et al. 1997;
Ziboh and Fletcher 1992). However, hepatic metabolism of
GLA to AA by Δ-5 desaturase increases circulating free AA
levels, which has the potential of neutralizing DGLA’sp o t e n -
tial as a leukotriene synthesis modifier (Ferretti et al. 1997;
Johnson et al. 1997; Kelley et al. 1997; Seyberth et al. 1975).
Supplementation of diet with long chain omega-3 fatty acids
such as eicosapentaenoic acid (EPA) found in fish oils have
been shown to compete with DGLA at the Δ-5 desaturase
step preventing elevations in AA as a result of providing
GLA in borage oil (Barham et al. 2000; Surette et al.
2008). In the current study, the botanical omega-3 PUFA,
stearidonic acid (SDA) from the seed oil of echium
(Echium plantagineum) was utilized because it bypasses
the rate-limiting Δ-6 desaturase in long chain, omega-3
PUFA biosynthesis and thus is efficiently converted to EPA.
Because the effects of botanical omega-3 and omega-6
PUFAs on asthma had not previously been studied, we
sought to determine whether borage and echium oils
provided in the ratio defined in our preliminary dose-
titration study could impact FEV1 when compared with
a placebo in a small, crossover study of stable asthmatics
(Arm et al. 2013). In our study, none of the secondary
outcomes, including asthma symptoms, rescue inhaler
use and peak expiratory flow, improved either in the
cohort as a whole or in either genotype group. This is
likely because the majority of participants enrolled in
the study were relatively well-controlled and the study
was likely underpowered to identify these differences.
It is well known that FEV1 measurements show sub-
stantial heterogeneity in response to treatments, includ-
ing to 5-LO inhibitors (Drazen et al. 1999), CysLT1
receptor antagonists (Tantisira and Drazen 2009), and
even the gold standard therapy of inhaled glucocorti-
coids (Tantisira et al. 2011). Since we anticipated that
any therapeutic benefit of the botanical omega-3 and
omega-6 lipids would reflect a modulatory effect on LT
generation, we performed a pre-specified analysis of
genotyping at the LTC4Sl o c u sf o rt h ec o m m o nAt oC
variant that has been associated with numerous out-
comes reflective of altered CysLT generation (Asano
et al. 2002; Acevedo et al. 2007; Sayers et al. 2003). We
observed two distinct effects of the variant C allele on
the response to the botanical oil supplementation. First,
the C allele carriers showed a net difference of 7% in
FEV1 between the placebo corn oil and botanical oil arms
(Figure 3), and all 9 of them demonstrated their highest
FEV1 measurements while on the study botanical combin-
ation (Figure 4). In contrast, the A allele homozygotes
showed no change in FEV1 at any time during the course
of the study. The 7% difference in FEV1 is comparable to
the efficacy of montelukast seen in patients with mild
persistent asthma with near-normal lung function (Barnes
et al. 2001).
Second, the granulocytes from the C allele carriers, but
not those from the A allele homozygotes, showed a transi-
ent but significant, reduction in overall 5-LO product for-
mation in response to ionophore (Figure 5). In contrast to
our preliminary dose-titration study, in which botanical
oil effects on LT formation by granulocytes and basophils
were compared to pre-treatment levels, the second study
involved a corn oil placebo. Thus, we cannot exclude the
possibility that the corn oil (containing relatively high
levels of the omega-6 PUFA, linoleic acid) could have
altered LT generation so as to modify the evident effect of
the botanicals. Indeed, this seemed to be the case for
FEV1, in which the difference was due to both an increase
in FEV1 with the botanical oils and a decrease in FEV1
with the corn oil – an observation that was restricted to
the C allele carriers (Figure 5a). Since the effect of the
botanicals was significant for total 5-LO pathway products
and for non-CysLTs (Figure 5), we suspect that the variant
LTC4S allele may alter the response of the 5-LO pathway
to dietary omega-3 and omega-6 PUFAs in a manner inde-
pendent of its primary function of conjugating LTA4 to
glutathione, perhaps from an epistatic effect.
In summary, we conclude that as compared to corn oil,
a combination of borage and echium seed oils containing
1.7 g/day of γ-linolenic acid and 0.8 g/day of stearidonic
acid improves airflow obstruction in mild to moderate
asthmatics who carry the variant allele in the LTC4 syn-
thase gene promoter (A-444C). Our findings suggest that
botanical oil supplementation can have therapeutic poten-
tial in asthma if used in a personalized manner. Further
studies examining the effects of botanical oil combinations
in asthma are warranted.
Methods
We designed a randomized, double-blind, placebo-
controlled, cross-over clinical trial (Figure 6). The
protocol was approved by the Partners Human Subjects
Research Committee. An investigator-initiated IND was
obtained from the US Food and Drug Administration
(IND number 74,110). Mild to moderate asthmatics with
a physician diagnosed history of asthma and the presence
of variable airflow obstruction were recruited. Patients on
leukotriene modifiers, oral or high dose inhaled steroids,
theophylline or omalizumab (a monoclonal antibody against
Immunoglobulin E) were excluded. Medical and respiratory
history, a brief physical examination and routine laboratory
tests were conducted at the screening visit to exclude the
presence of significant co-morbid diseases.
The study design is depicted in Figure 6. The primary
outcome was pre-specified to be the difference in the
change in forced expiratory volume in one second (FEV1)
after three weeks of therapy between combination botanical
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the KoKo Spirometry software. Pre-specified secondary
analyses included the examination of the effect of A-444C
polymorphism of the LTC4Sg e n eo nF E V 1, rescue inhaler
use, daily symptoms documented in diary cards, daily lung
function assessed with Jaeger electronic peak flow meters,
leukotriene generation from peripheral white blood cells in
response to a range of stimulus doses and urine LTE4 mea-
surements. Details of assays used for measurements are
provided in the online resource accompanying the manu-
script. Blood from participants was collected weekly for
assessment of hematological indices, liver and renal func-
tion. Medication compliance was monitored by medication
diaries, counts of returned capsules, and plasma fatty acids
measurements.
Capsules containing a combination of borage and echium
seed oils were obtained from Croda Europe Ltd (Leek,
Staffordshire, UK). Subjects randomized to receive drug
were given nine 1 g capsules (7 with echium and 2 with
borage oil) each day, for a total of 1.57 g and 0.87 g
gamma-linolenic acid (GLA) and stearidonic acid (SDA),
respectively, per day. Subjects randomized to placebo
received 9 capsules of corn oil each day. Each 1 gram
capsule of corn oil contained no GLA or SDA and 560 mg
of linoleic acid (the major fatty acid in corn oil) for a total
dosage of 5 g of linoleic acid. The typical Western diet
contains very high levels of linoleic acid (6-8% of daily
energy) so this supplementation protocol would add a very
small percentage of the linoleic acid found in the typical
modern Western diet.
We used Student’s t-tests to compare normally
distributed data, Wilcoxon rank sum tests for unpaired
non-parametric data and Wilcoxon signed rank tests
for paired non-parametric data. Categorical data were ana-
lyzed using two-sided Fisher’s exact tests. We employed
repeated measures mixed model analysis in which repeated
measures were taken on each subject at each visit (time) and
the group and time interactions were modeled with the main
effects. A compound symmetry correlation structure was
used since the correlation between pairs of times would be
similar and not expected to change across time. Data were
analyzed using SAS 9.1 (SAS Institute Inc., Cary, NC, USA)
where the significance level is set at 95%. All subjects were
genotyped for their LTC4S A-444C polymorphism status at
the Harvard Partners Center for Genetics and Genomics
(HPCGG) by using either Sequenom MassARRAY system
(Sequenom, San Diego, CA) or Taqman analysis on the
Applied Biosystems 7900HT system (Applied Biosystems,
Forster City, California, USA) based on assay availability in
the laboratory. Quality control was assured by running
internal and external controls on all genotyping plates.
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